Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2026-05-11 16:58:56 ET · period of report 2026-05-11 · accession 0001193125-26-217041 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-11 16:58 | 2026-05-11 | KYMR | Ridloff Elena | Dir | M - OptEx | $31.20 | +3,000 | 3,000 | New | +$93.6K |
| DT | 2026-05-11 16:58 | 2026-05-11 | KYMR | Ridloff Elena | Dir | S - Sale+OE | $87.00 | -3,000 | 0 | -100% | -$261.0K |
| DT | 2026-05-11 16:58 | 2026-05-11 | KYMR | Ridloff Elena | Dir | M - OptEx | $0.00 | -3,000 | 13.0K | -19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-11 | M | A | 3,000 | $31.20 | 3,000 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. |
| 2 | Common | Common Stock | 2026-05-11 | S | D | 3,000 | $87.00 | 0 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-05-11 | M | D | 3,000 | $0.00 | 13,000 | D | $31.20 · — to 2034-06-17 | 3,000 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 11, 2025 adopted by the reporting person. (F2) The shares underlying this stock option are fully vested and exercisable. |